T Gräser

The influence of a combined estrogen-progestin regimen (Climodien) on noopsyche, thymopsyche, personality and psychophysiological measures of menopausal syndrome patients was investigated in a double-blind, placebo-controlled, comparative, …

OBJECTIVE: This randomized, double-blind, placebo-controlled study was planned to investigate the effects of continuous combined hormone replacement therapy (HRT) with 2 mg estradiol valerate and 2 mg dienogest (Climodien/Lafamme) over 24 w…

Differences in sleep and awakening quality between 51 insomniac postmenopausal syndrome patients and normal controls were evaluated. In a subsequent double-blind, placebo-controlled, comparative, randomized, three-arm trial (Climodien 2/3 =…

OBJECTIVE: To evaluate the efficacy, safety and tolerability of continuous combined hormone replacement therapy (HRT) with Climodien (estradiol valerate 2 mg plus dienogest 2 mg). DESIGN: Open, multinational, multicenter, non-controlled pha…

Objective To evaluate the efficacy, safety and tolerability of continuous combined hormone replacement therapy (HRT) with Climodien® (estradiol valerate 2 mg plus dienogest 2 mg). Design Open, multinational, multicenter, non-controlled phas…

The estradiol metabolism may be of clinical relevance in the pathophysiology of various diseases; the increase in D-ring metabolites over A-ring metabolites in breast cancer patients is of special interest. Since estrogen therapy has been b…

The effects of two oral contraceptive combinations, dienogest 2.0 mg plus ethinyl estradiol 0.03 mg (Valette) and desogestrel 0.15 mg plus ethinyl estradiol 0.02 mg (Lovelle), on the human immune system were compared over one treatment cycl…

Objective To compare the efficacy and endometrial safety of two estradiol valerate/dienogest combinations with Kliogest® in the treatment of postmenopausal symptoms.Design This was a double-blind, randomized, multicenter study.Methods Patie…

Studies have been undertaken to investigate the modulatory effects of a combination of 30 μg ethinylestradiol and 2.00 mg dienogest (Valette®) on ovarian function and on the hemostatic system. Modulation of ovarian function was investigated…

Dienogest is the first non-alkylated 19-norprogestin on the market. This so-called hybrid progestin combines the typical qualities of the modern 19-norprogestins with those of natural progesterone and synthetic hydroxyprogesterone derivativ…

Ziel: Dienogest (DNG, 17alpha-Cyanomethyl-17beta-hydroxy-4,9- estradien-3-on) repräsentiert einen neuen Typ der 19-Norgestagene. Es zeigt bezüglich der antiandrogenen Partialwirkung Ähnlichkeiten zu den C21-Progesteronderivaten. Deshalb sol…

Antiandrogens or progestins with an antiandrogenic component usually have only a weak antigonadotropic activity. It is thus possible that the antiandrogenic effect on the cellular level is cancelled or at least reduced by an increased ovari…